TIMOPTIC IN OCUDOSE Drug Patent Profile

Which patents cover Timoptic In Ocudose, and what generic alternatives are available?

Timoptic In Ocudose is a drug marketed by Bausch And Lomb Inc and is included in one NDA.

The generic ingredient in TIMOPTIC IN OCUDOSE is timolol maleate. There are fifteen drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the timolol maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Timoptic In Ocudose

A generic version of TIMOPTIC IN OCUDOSE was approved as timolol maleate by MYLAN on June 8^th, 1990.

Summary for TIMOPTIC IN OCUDOSE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	75
Patent Applications:	5,143
Drug Prices:	Drug price information for TIMOPTIC IN OCUDOSE
What excipients (inactive ingredients) are in TIMOPTIC IN OCUDOSE?	TIMOPTIC IN OCUDOSE excipients list
DailyMed Link:	TIMOPTIC IN OCUDOSE at DailyMed

See drug prices for TIMOPTIC IN OCUDOSE

Pharmacology for TIMOPTIC IN OCUDOSE

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for TIMOPTIC IN OCUDOSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-001	Nov 5, 1986	AT3	RX	Yes	Yes
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-002	Nov 5, 1986	AT3	RX	Yes	Yes

Expired US Patents for TIMOPTIC IN OCUDOSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-001	Nov 5, 1986
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-002	Nov 5, 1986
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-001	Nov 5, 1986
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-002	Nov 5, 1986

International Patents for TIMOPTIC IN OCUDOSE

See the table below for patents covering TIMOPTIC IN OCUDOSE around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	288378
Austria	289788
Austria	289789
Austria	294830
Austria	295526

Supplementary Protection Certificates for TIMOPTIC IN OCUDOSE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0227494	95C0013	Belgium		PRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
0509752	C990041	Netherlands		PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
0509752	SPC/GB99/043	United Kingdom		PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
0509752	2000C/001	Belgium		PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
0509752	49/1999	Austria		PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306

Last updated: July 30, 2026

Timoptic in Ocudose (timolol maleate ophthalmic solution): Market dynamics and financial trajectory

Executive summary: Timoptic in Ocudose (timolol maleate ophthalmic solution in an Ocudose unit-dose delivery system) remains a niche but durable revenue product in the glaucoma market, with sales driven by ongoing ophthalmic demand for intraocular pressure (IOP) lowering, refill-adherence from unit-dose packaging, and prescriber familiarity with timolol. Financial trajectory is shaped primarily by (1) competitive pricing pressure from generic timolol ophthalmic solutions and (2) substitution dynamics within the beta-blocker class, plus (3) payer and channel incentives that favor lowest net cost. Patent and exclusivity leverage for the Ocudose-specific delivery and/or listed formulation patents typically limits generic substitution of the Ocudose format even when API exclusivity ends, but the overall financial ceiling is constrained by broad class generic availability for timolol.

What drives Timoptic in Ocudose sales in glaucoma treatment?

Core demand engine: Timolol is a long-established, first-line beta-blocker for lowering IOP in open-angle glaucoma and ocular hypertension. Timoptic’s unit-dose Ocudose format aims to reduce bottle contamination risk and support adherence for chronic daily therapy. Market pull depends more on prescribing inertia, channel access, and pharmacy fill behavior than on clinical differentiation versus other timolol generics.

Primary sales drivers

• Chronic use and switching within beta-blockers: Patients and prescribers often switch between beta-blockers (timolol, betaxolol) or adjunctive classes (prostaglandin analogs, carbonic anhydrase inhibitors) based on tolerance and IOP response. Timolol’s position is protected mainly by cost and guideline familiarity, not by unique efficacy.
• Adherence economics: Ocudose packaging can reduce preservative-related concerns and simplify dosing without sharing a multi-use bottle. In markets where adherence metrics are tied to outcomes programs, unit-dose packaging can improve persistence versus multidose bottles.
• Formulary placement: Net sales correlate with pharmacy channel support, rebate structures, and generic substitution rules. Timolol ophthalmics are typically treated as therapeutically equivalent across multiple products and strengths, putting pricing power under pressure.

Key commercial implication

• Even if Ocudose format faces fewer direct same-format competitors than traditional multidose bottles, the product still competes against generic timolol ophthalmic solutions on net price, limiting upside.

How does unit-dose packaging affect substitution risk versus generic timolol drops?

Ocudose can lower substitution risk in practice when prescribers write for the specific delivery format or when patients perceive handling and comfort benefits. However, substitution can still occur at the pharmacy if generics are deemed equivalent and if formulary rules permit interchange.

How fast is the timolol ophthalmic market commoditizing for Timoptic in Ocudose?

Market structure: Timolol ophthalmic solutions are widely genericized globally. In the US, most timolol products are available as generics, and the competitive field includes multiple manufacturers and package formats. That structure drives price compression across the category.

Commoditization timeline (typical for established ophthalmics)

• Early lifecycle: Brand holds premium pricing and has differentiation through packaging, channel execution, and prescriber education.
• Generic build: As multiple ANDAs launch and expand coverage across strengths, package sizes, and dosing regimens, price competition accelerates.
• Mature stage: Net pricing stabilizes at a low band, with sales shift toward products with strongest distribution and formulary rebates rather than clinical differentiation.

Ocudose-specific dynamic

• The delivery system can slow direct format competition if there is limited same-format generic entry. Still, that effect usually narrows to channel share rather than market expansion because the active ingredient is commoditized.

What does the financial trajectory look like for Timoptic in Ocudose versus generic timolol?

A realistic financial trajectory for a packaged brand in a generic API class is typically characterized by:

• Revenue deceleration after API generic launches (market share and list-price decline).
• Stabilization if the brand retains distribution and prevents full conversion to cheaper equivalents.
• Further decline with additional generic entries, especially when the market moves to lowest-cost formulary tiers.

Profit and cashflow implications for investors/licensors

• Gross margin compression: generics cap net pricing. Any Ocudose-specific differentiation that raises manufacturing cost tends to be offset by pharmacy-level pricing pressure.
• Marketing efficiency matters: the brand must rely on targeted retention (patient support, prescriber pull, refill programs) rather than broad growth.
• Channel concentration: sales in mature ophthalmics increasingly track with wholesaler and payer contracts that favor certain SKUs.

What is the competitive landscape for timolol ophthalmic solutions and Ocudose packaging?

Competitor set

• Generic timolol ophthalmic solutions in bottle and unit-dose presentations.
• Other beta-blockers (e.g., betaxolol in markets where covered).
• Substitution threats from prostaglandin analogs (e.g., latanoprost, travoprost, bimatoprost) and combination products that can displace timolol when clinicians seek once-daily convenience or higher IOP lowering.

Competitive pressure channels

• Net price: generics force markdowns through rebate negotiations and formulary tiering.
• Dispensing substitution: pharmacy-level interchangeable alternatives shift fills.
• Clinical substitution: prostaglandin-first guidelines and real-world practice increase displacement risk over time.

How does Timoptic in Ocudose compare with standard timolol multidose drops?

• Advantage: unit-dose handling and reduced bottle contamination risk.
• Tradeoff: higher cost to manufacture and potentially lower payer acceptance if unit-dose SKUs do not show measurable adherence gains in that payer population.
• Net outcome: unit-dose formats often retain niche share but rarely reverse category pricing pressure.

What patents protect Timoptic in Ocudose and how does that affect financial resilience?

For a branded ophthalmic with a proprietary delivery system, the financial story is usually tied to whether exclusivity covers:

• the formulation,
• the delivery device or unit-dose architecture,
• the manufacturing method, and/or
• listed packaging characteristics that affect generic “substantially similar” entry.

How patent coverage changes revenue

• If listed patents delay generic Ocudose-equivalent products, the brand can sustain sales longer and keep net pricing above generic baseline.
• If patents cover only narrow aspects and generic entrants can design around them, the revenue window shrinks.

Business impact

• A brand’s bargaining position with payers improves during the remaining patent shelf.
• Licensing value increases if exclusivity extends beyond the API horizon into delivery/packaging.

When does Timoptic in Ocudose lose exclusivity?

Exclusivity timing for a product in a generic API class usually splits into:

• Patent expiration / regulatory exclusivity that blocks identical format generics
• Loss of marketing premium due to generic price convergence, which can occur even before all delivery-related patents expire if payers and pharmacies substitute based on therapeutic equivalence.

Because this is a market dynamics request, the practical loss date is when net pricing and channel access shift materially from brand-preferred ordering to generic default ordering.

What generic entry risks exist for Timoptic in Ocudose?

Primary risks

• ANDA approvals for timolol with interchangeable strength and dosing that can substitute at the pharmacy.
• Design-around entry: delivery-system or manufacturing process changes that avoid listed patents.
• Broader formulary movement: even if a same-format generic is not available, payers can increase preference for cheaper timolol SKUs.

Settlement-driven risk

• If generic filers initiate patent litigation, settlements can include delayed launch terms, but these typically end with some “catch-up” conversion once delay expires or once generic design circumvents the settlement terms.

What Orange Book status applies to Timoptic in Ocudose?

Orange Book status determines two deal-critical items:

• whether there are listed patents tied to the approved drug product,
• whether any patents are systematically eligible to be challenged via Paragraph IV.

For a delivery-system brand, the key question is whether the listed patents cover the Ocudose-specific aspects that would be infringed by a generic with the same delivery format and packaging claim scope.

What patent litigation affects Timoptic in Ocudose?

Patent litigation affects market dynamics through:

• timing of generic launches,
• pricing uncertainty (channel hesitation during pending cases),
• settlement structure (carve-outs, launch dates, supply restrictions).

From a financial trajectory standpoint, the most material litigation effect is the gap between:

• a generic “ability-to-market” date (regulatory approval readiness), and
• the “ability-to-commercialize” date (effective launch after injunctions or settlement delay).

FDA and regulatory status: does pathway selection affect market timing?

For mature ophthalmic products, the commercial timeline is driven less by FDA pathway novelty and more by:

• ANDA approval readiness,
• labeling alignment (indications, dosing, preservatives),
• generic product packaging acceptance with pharmacies.

Unit-dose compatibility can matter because some payers or pharmacy benefit managers restrict coverage to specific NDC presentations.

How do payer contracts and wholesaler incentives shape net sales for Ocudose?

In ophthalmics, net sales are materially influenced by:

• rebates and price concessions that determine “net” competitiveness versus generic rivals,
• wholesaler stocking decisions that impact fill rates,
• formulary tiering that controls patient access.

Even when brand differentiation exists, payers often enforce cost minimization unless:

• unit-dose format yields measurable adherence improvements within that covered population, or
• the brand retains enough formulary access that the pharmacy cannot easily substitute.

What is the revenue exposure for the Timoptic in Ocudose business model?

Revenue exposure can be viewed as:

• core IOP-lowering demand within glaucoma/OHT,
• share retention versus generic timolol,
• incremental loyalty to unit-dose packaging.

The business risk is concentrated in scenarios where:

1. payers move the product out of preferred tiers,
2. additional generics enter with stronger rebate economics,
3. pharmacy interchange increases and prescribers stop specifying unit-dose.

Key takeaways

• Timoptic in Ocudose sells into a commoditized timolol category where financial upside is constrained by generic API competition.
• Unit-dose packaging can slow full substitution and support niche share, but it does not typically restore brand-level pricing power once generics saturate the market.
• Patent or exclusivity leverage tied to Ocudose-specific delivery, packaging, or formulation is the main factor that can extend revenue duration, but category pricing pressures can still erode net sales.
• The most consequential near-term market dynamic is payer and pharmacy conversion behavior as additional generic SKUs expand and as net cost advantages shift channel ordering.

FAQs

1. Does Timoptic in Ocudose have fewer generic competitors than multidose timolol drops?
2. How do formulary changes impact persistence for unit-dose glaucoma therapies like Ocudose?
3. Do patent settlements for ophthalmic ANDAs typically delay launch enough to protect quarterly revenue?
4. Which glaucoma drug classes most commonly displace timolol in real-world prescribing?
5. How does unit-dose packaging affect pharmacy interchange rules in the US?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drug Approval Packages: Labeling and Regulatory Information. U.S. Food and Drug Administration.